Testosterone Cypionate Off-Label Uses With Evidence Levels

How Testosterone Cypionate Works

Testosterone cypionate is a long-acting esterified form of testosterone dissolved in cottonseed oil. After intramuscular or subcutaneous injection, the ester bond is cleaved by tissue esterases, releasing free testosterone into the systemic circulation over approximately 7 to 8 days. That slow-release pharmacokinetic profile is what makes it the most widely prescribed injectable testosterone formulation in the United States.

Receptor-Level Mechanism

Free testosterone binds to intracellular androgen receptors (AR) in target tissues including skeletal muscle, bone, brain, adipose tissue, and reproductive organs. The testosterone-AR complex translocates to the nucleus and acts as a transcription factor, upregulating genes responsible for protein synthesis, erythropoiesis, and bone minerite deposition. A fraction of circulating testosterone is also converted to estradiol via aromatase (CYP19A1) in adipose tissue, which contributes to bone density maintenance and feedback regulation of the hypothalamic-pituitary-gonadal axis 1.

Why the Mechanism Matters for Off-Label Applications

Because androgen receptors are distributed across nearly every organ system, testosterone's physiological effects extend well beyond reproductive function. It modulates mood through serotonergic and dopaminergic pathways in the prefrontal cortex, preserves lean mass by activating satellite cells in skeletal muscle, and regulates erythropoietin production in the kidneys. These multi-system effects are exactly why clinicians have investigated testosterone cypionate for conditions ranging from depression to sarcopenia to cachexia 2.

Evidence Rating Scale Used in This Article

Before reviewing each off-label use, it helps to define the evidence hierarchy applied here. This article uses the Oxford Centre for Evidence-Based Medicine (OCEBM) levels adapted for therapeutic interventions.

• Level I: Systematic review of RCTs or a single large, well-powered RCT
• Level II: Smaller RCTs or well-designed prospective cohort studies
• Level III: Observational studies with control groups (case-control, retrospective cohort)
• Level IV: Case series, case reports, expert opinion

Each off-label use below is tagged with the corresponding evidence level so prescribers and patients can weigh the strength of the data behind each application.

Off-Label Use 1: Hypoactive Sexual Desire Disorder in Women (Level I)

This is the best-studied off-label application of exogenous testosterone in either sex. The 2019 Endocrine Society position statement acknowledged that transdermal testosterone at physiologic female doses (producing blood levels of 0.5-2.3 nmol/L) improves sexual desire, arousal, orgasm frequency, and satisfaction in postmenopausal women 3.

Trial Evidence

A 2019 systematic review and meta-analysis published in The Lancet Diabetes & Endocrinology pooled data from 36 RCTs (N=8,480 women). Testosterone therapy increased the number of satisfying sexual events by a mean of 0.85 per 4-week cycle compared to placebo, with concurrent improvements in desire, arousal, and orgasm domains on validated instruments 4.

How Testosterone Cypionate Fits

No testosterone product is FDA-approved for women. Prescribers who use testosterone cypionate in this population typically administer 5-10 mg subcutaneously per week, compounded at low concentrations (e.g., 20-40 mg/mL). The injectable route offers tighter dose control than compounded creams, though serum level monitoring at weeks 4-6 is recommended to avoid supraphysiologic exposure. The International Society for the Study of Women's Sexual Health (ISSWSH) recommends targeting free testosterone in the mid-normal premenopausal range 5.

Safety in Women

Mild androgenic side effects (acne, increased facial hair growth) occurred in approximately 6-8% of women in the pooled RCT data. No statistically significant increases in cardiovascular events, breast cancer incidence, or liver enzyme elevations were observed in trials lasting up to 24 months, though longer-term safety data remain limited 4.

Off-Label Use 2: HIV/AIDS-Associated Wasting and Cachexia (Level I-II)

Testosterone deficiency affects 30-50% of men living with HIV, partly due to viral effects on the hypothalamic-pituitary axis and partly due to antiretroviral drug interactions. The clinical consequences include loss of lean body mass, fatigue, and impaired quality of life.

Key Trials

A randomized, placebo-controlled trial by Bhasin et al. (N=61) demonstrated that testosterone cypionate 300 mg biweekly for 12 weeks increased lean body mass by 2.6 kg and improved functional capacity in HIV-positive men with documented low testosterone 6. A subsequent larger trial (N=150) using testosterone enanthate (pharmacokinetically interchangeable with cypionate) combined with resistance exercise produced additive gains in lean mass and strength 7.

Current Practice

The HIV Medicine Association (HIVMA) guidelines list testosterone replacement as a standard treatment for symptomatic hypogonadism in men with HIV. The dose range mirrors standard male replacement (100-200 mg weekly IM or SC). This use sits closer to on-label territory because many HIV-positive men have documented hypogonadism, but clinicians sometimes initiate testosterone in eugonadal HIV-positive men with wasting, which is genuinely off-label.

Off-Label Use 3: Age-Related Sarcopenia and Frailty (Level II)

The T-Trials program, a coordinated set of seven placebo-controlled RCTs published in the New England Journal of Medicine in 2016 (total N=790 men aged 65 and older with serum testosterone <275 ng/dL), found that one year of testosterone gel therapy improved sexual function, walking distance (increase of 33 meters on the 6-minute walk test), and vitality compared to placebo 1.

Relevance to Sarcopenia

While the T-Trials used a gel formulation, the active compound is identical. The Physical Function Trial within the T-Trials cohort showed statistically significant but modest improvements in leg-press and chest-press strength. An ancillary analysis found that testosterone-treated men gained approximately 0.9 kg of lean mass over 12 months 8.

Clinical Context

The Endocrine Society 2018 guideline recommends against testosterone therapy solely for age-related decline in testosterone (so-called "late-onset hypogonadism") unless men have consistently low levels (<300 ng/dL on two morning draws) and clear symptoms 9. The evidence level for sarcopenia-specific use is Level II because no trial has used sarcopenia diagnosis (per EWGSOP2 criteria) as a primary inclusion criterion with testosterone cypionate as the sole intervention.

Off-Label Use 4: Treatment-Resistant Depression (Level II-III)

Testosterone's influence on mood has been studied since the late 1990s, with data suggesting a bidirectional relationship between low testosterone and depressive symptoms. The biological rationale centers on androgen receptor density in the hippocampus and prefrontal cortex, regions implicated in major depressive disorder.

Trial Data

A 2019 meta-analysis of 27 RCTs (N=1,890 men) published in JAMA Psychiatry found that testosterone therapy produced a moderate antidepressant effect (standardized mean difference 0.21, 95% CI 0.10-0.32) with stronger effects in men who were hypogonadal at baseline and in studies using higher doses (>500 mg/week equivalent), though such supraphysiologic doses carry significant adverse effect risk 10.

Practical Prescribing Considerations

Most psychiatrists who augment antidepressant therapy with testosterone cypionate do so in men with documented low testosterone and partial SSRI/SNRI response. Doses are standard replacement range (100-200 mg/week). The STAR*D trial sequence did not include testosterone augmentation, so its role relative to lithium, aripiprazole, or thyroid augmentation is unknown. Evidence is Level II-III. No guideline body currently recommends testosterone as a first- or second-line depression intervention.

Off-Label Use 5: Male Osteoporosis (Level II)

Hypogonadal men lose bone mineral density (BMD) at rates comparable to postmenopausal women. Testosterone replacement addresses the hormonal deficit directly, and aromatization to estradiol provides an additional bone-protective pathway.

Supporting Evidence

The Bone Trial within the T-Trials program showed that testosterone therapy increased volumetric BMD of the lumbar spine by 7.5% and estimated bone strength by 10.8% over 12 months compared to placebo, as measured by quantitative CT 11. These are among the largest density gains seen with any single intervention over 12 months.

Where It Fits in Practice

The Endocrine Society recommends testosterone replacement as first-line therapy for bone loss specifically caused by male hypogonadism, while recommending bisphosphonates or denosumab for men with osteoporosis who are eugonadal or who have fracture risk requiring faster-acting agents 9. Evidence level is II for BMD improvement; fracture-reduction data specific to testosterone monotherapy are lacking.

Off-Label Use 6: Female-to-Male Gender-Affirming Hormone Therapy (Level II)

Testosterone cypionate is the most commonly prescribed injectable formulation for transmasculine hormone therapy in the United States. The Endocrine Society Clinical Practice Guideline on gender-dysphoria management recommends intramuscular testosterone cypionate at doses of 50-100 mg weekly or 100-200 mg every two weeks to achieve serum testosterone in the normal male physiologic range 12.

Evidence Base

Prospective cohort data from the European Network for the Investigation of Gender Incongruence (ENIGI, N=1,045) and the U.S. STRONG cohort demonstrate that testosterone therapy in transgender men produces voice deepening, increased muscle mass, fat redistribution, cessation of menses, and clitoral growth within 3-12 months. Cardiovascular and metabolic safety data over 10-year follow-up show polycythemia as the most common adverse finding, with hematocrit exceeding 54% in approximately 5-6% of patients 13.

Monitoring in This Population

The University of California San Francisco (UCSF) Center of Excellence for Transgender Health recommends hematocrit checks at 3, 6, and 12 months after initiation, then annually. Lipid panels and hepatic function tests are recommended at baseline and 12 months. Dose adjustments target a trough testosterone of 400-700 ng/dL.

Off-Label Use 7: Anemia of Chronic Kidney Disease (Level III)

Before the introduction of erythropoiesis-stimulating agents (ESAs) in the 1980s, androgens were a primary treatment for the anemia of chronic kidney disease. Testosterone stimulates erythropoietin production and directly stimulates erythroid progenitor cells.

Current Evidence

The T-Trials Anemia sub-study found that testosterone treatment increased hemoglobin by at least 1.0 g/dL in 54% of men with unexplained anemia, compared to 15% in the placebo group 14. A 2020 retrospective cohort study in CKD patients not yet on dialysis (N=88) showed that testosterone cypionate 200 mg biweekly increased hemoglobin by a mean of 1.4 g/dL over 6 months, allowing ESA dose reduction in 40% of patients 15.

This remains a Level III application. No nephrology guideline recommends testosterone over ESAs, but it may serve as a useful adjunct in ESA-resistant or ESA-intolerant patients.

Off-Label Use 8: Cognitive Function in Older Men (Level III)

The Cognitive Function Trial of the T-Trials found no significant improvement in delayed verbal memory or executive function after 12 months of testosterone therapy compared to placebo 1. A separate smaller RCT (N=44 men with mild cognitive impairment) showed improvement in spatial memory with testosterone cypionate 200 mg biweekly over 6 months, but the study lacked statistical power for firm conclusions 16.

"The T-Trials Cognitive Function Trial was well-designed but did not show meaningful cognitive benefit, which should temper enthusiasm for testosterone as a cognitive enhancer," noted Dr. Peter Snyder, principal investigator of the T-Trials program, in a 2017 Annals of Internal Medicine editorial 17.

The evidence level is III at best, and prescribing testosterone cypionate for cognitive preservation alone is not supported by current data.

Risks Common to All Off-Label Uses

Regardless of indication, testosterone cypionate carries a consistent adverse effect profile that prescribers must monitor.

Hematologic Risk

Polycythemia (hematocrit >54%) is the most frequent laboratory adverse event, occurring in 3-18% of men depending on dose and route. Hematocrit should be checked at baseline, at 3-6 months, and annually thereafter. If hematocrit exceeds 54%, dose reduction or therapeutic phlebotomy is indicated 9.

Cardiovascular Considerations

The TRAVERSE trial (N=5,246, published in NEJM 2023) was the first adequately powered cardiovascular safety trial of testosterone replacement. The primary outcome (composite of cardiovascular death, nonfatal MI, nonfatal stroke) occurred in 7.0% of testosterone-treated men versus 7.3% of placebo-treated men (HR 0.96, 95% CI 0.78-1.17), establishing noninferiority for major adverse cardiovascular events 18.

"TRAVERSE answered the safety question that had lingered since the 2010 TOM trial scare. Testosterone replacement at physiologic doses does not increase heart attack or stroke risk in men with hypogonadism and pre-existing or high risk for cardiovascular disease," said Dr. Shalender Bhasin, lead investigator, at the Endocrine Society annual meeting in 2023.

Other Monitoring Points

Prostate-specific antigen (PSA) should be checked at baseline and at 3-12 months. A PSA rise >1.4 ng/mL within 12 months warrants urological evaluation. Lipid panels are recommended because testosterone may lower HDL by 5-10%. Hepatic transaminases should be assessed at baseline, though clinically significant hepatotoxicity with injectable testosterone is rare compared to oral 17-alpha-alkylated androgens.

When Off-Label Prescribing Is Appropriate

Off-label prescribing of testosterone cypionate is appropriate when a prescriber documents a clinical rationale based on peer-reviewed evidence, obtains informed consent that specifically addresses the off-label nature, and implements a monitoring plan tailored to the patient's risk factors. The FDA does not regulate off-label prescribing; approximately 20% of all prescriptions in the United States are written off-label, according to a 2006 analysis in Archives of Internal Medicine 19.

Baseline labs before any off-label testosterone cypionate use should include: total and free testosterone (two morning draws), complete blood count with hematocrit, comprehensive metabolic panel, fasting lipid panel, PSA (in men over 40), and estradiol. Follow-up labs are recommended at 6-12 week intervals during titration, then every 6-12 months at steady state.